1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Epilepsy Drugs Market in Europe - Market Analysis 2015-2019

Epilepsy Drugs Market in Europe - Market Analysis 2015-2019

  • September 2015
  • -
  • Infiniti Research Limited
  • -
  • 64 pages

About epilepsy
Epilepsy refers to a spectrum of brain disorders manifested by benign to severe, disabling, and life-threatening symptoms. It is caused by factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and trauma during birth. When the underlying cause of the disease is unidentified, as is witnessed in the majority of cases, it is known as idiopathic epilepsy. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures.

Technavio's analysts forecast the epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the epilepsy drugs market in Europe for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of epilepsy.

Technavio's report, Epilepsy Drugs Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key Vendors
- Eisai
- GlaxoSmithKline
- Pfizer
- UCB

Other prominent vendors
- AbbVie
- Janssen Pharmaceuticals
- Lundbeck
- Meda
- Novartis
- Roche
- Shire
- Sunovion Pharmaceuticals
- Supernus Pharmaceuticals
- Upsher-Smith
- Valeant Pharmaceuticals

Market driver
- Unmet medical needs
- For a full, detailed list, view our report

Market challenge
- Patent expiry
- For a full, detailed list, view our report

Market trend
- Reformulation of marketed drugs
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Epilepsy Drugs Market in Europe - Market Analysis 2015-2019
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Epilepsy: An overview
About the disease
Types of epilepsy
Signs and symptoms
Diagnosis
Epidemiology
Economic burden
PART 06: Pipeline portfolio
Key information of few pipeline candidates
PART 07: Market landscape
Market overview
Epilepsy drugs market in Germany
Epilepsy drugs market in the UK
Five forces analysis
PART 08: Market segmentation by generation of drugs
Segmentation of epilepsy drugs market in Europe by generation of drugs
PART 09: Market drivers
Unmet medical needs
Rise in patient population
Promising drug pipeline
PART 10: Impact of drivers
PART 11: Market challenges
Expiry of patents
Stringent regulatory guidelines
Social stigma associated with epilepsy
PART 12: Impact of drivers and challenges
PART 13: Market trends
Reformulation of marketed drugs
Emergence of new-generation anti-epileptic drugs
PART 14: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 15: Key vendor analysis
Eisai
GlaxoSmithKline
Pfizer
UCB
PART 16: Appendix
List of abbreviations
PART 17: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Cost per person in Europe 2010
Exhibit 03: Pipeline portfolio
Exhibit 04: Epilepsy drugs market in Europe 2014-2019 ($ millions)
Exhibit 05: Epilepsy drugs market in Europe 2014
Exhibit 06: Epilepsy drugs market in Germany 2014-2019 ($ millions)
Exhibit 07: Epilepsy drugs market in the UK 2014-2019 ($ millions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of epilepsy drugs market in Europe by generation of drugs
Exhibit 10: Impact of drivers
Exhibit 11: Impact of drivers and challenges
Exhibit 12: Eisai: Key takeaways
Exhibit 13: Eisai: Fycompa product profile
Exhibit 14: Eisai: Revenue of Fycompa in EMEA 2013 and 2014 ($ millions)
Exhibit 15: Eisai: Inovelon product profile
Exhibit 16: Eisai: Revenue of Inovelon in EMEA 2013 and 2014 ($ millions)
Exhibit 17: Eisai: Zebinix product profile
Exhibit 18: Eisai: Revenue of Zebinix in EMEA 2013 and 2014 ($ millions)
Exhibit 19: Eisai: Zonegran product profile
Exhibit 20: Eisai: Revenue of Zonegran 2013 and 2014 ($ millions)
Exhibit 21: GlaxoSmithKline: Key takeaways
Exhibit 22: GlaxoSmithKline: Lamictal product profile
Exhibit 23: GlaxoSmithKline: Revenue of Lamictal in Europe 2011-2014 ($ millions)
Exhibit 24: GlaxoSmithKline: Trobalt product profile
Exhibit 25: Pfizer: Key takeaways
Exhibit 26: Pfizer: Lyrica product profile
Exhibit 27: Pfizer: Revenue of Lyrica 2011-2014 ($ millions)
Exhibit 28: Pfizer: Neurontin product profile
Exhibit 29: Pfizer: Revenue of Neurontin 2011-2013 ($ millions)
Exhibit 30: UCB: Key takeaways
Exhibit 31: UCB: Keppra product profile
Exhibit 32: UCB: Revenue of Keppra in Europe 2011-2014 ($ millions)
Exhibit 33: UCB: Vimpat product profile
Exhibit 34: UCB: Revenue of Vimpat in Europe 2011-2014 ($ millions)
Exhibit 35: UCB: Product segmentation by revenue 2014
Exhibit 36: UCB: Product segmentation by revenue 2013 and 2014
Exhibit 37: UCB: Geographical segmentation by revenue 2014
Exhibit 38: UCB: Geographical segmentation by revenue 2013 and 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Cardiovascular Surgical Devices: Technologies and Global Markets

Cardiovascular Surgical Devices: Technologies and Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about the trends and developments affecting each type of cardiovascular surgical technology - Analyze trends and opportunities in major regions: North America, Europe, Asia ...

TCR/CAR-T Therapies in Oncology: Analytical Tool

TCR/CAR-T Therapies in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.